Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Cellectis SA ( (CLLS) ).
On January 8, 2026, Cellectis outlined its 2026 strategy and key clinical and partnership milestones, underscoring its transition in 2025 into a late-stage allogeneic CAR-T developer with the start of the pivotal Phase 2 BALLI-01 trial of lasme-cel in relapsed or refractory B-ALL. The company plans a first interim analysis of this Phase 2 study in the fourth quarter of 2026, supported by previously reported Phase 1 data showing strong response rates, survival signals and a favorable safety profile, while in non-Hodgkin lymphoma it aims to expand its dual-target CAR-T candidate eti-cel by adding an IL-2–supported cohort in early 2026 and releasing full Phase 1 results, including IL-2 data, in the fourth quarter. Cellectis also highlighted progress under its research collaboration with AstraZeneca to develop up to 10 novel cell and gene therapies, as well as value-creating milestones from partners Servier/Allogene and Iovance across CD19, CD70 and TIL programs, and said its current cash resources should fund operations into the second half of 2027 as it engages investors at the J.P. Morgan Healthcare Conference in mid-January 2026.
The most recent analyst rating on (CLLS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s overall stock score is primarily influenced by its strong technical indicators, which suggest positive market momentum. However, the company’s financial performance and valuation are concerning due to persistent unprofitability and negative cash flow, which significantly impact the score.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a clinical-stage biotechnology company specializing in gene-edited cell and gene therapies, with a focus on allogeneic, off-the-shelf CAR-T immunotherapies for oncology and gene therapies in other indications. Leveraging an in-house gene-editing platform and end-to-end manufacturing capabilities, the company operates from headquarters in Paris with sites in New York and Raleigh, and its shares trade on Nasdaq and Euronext Growth.
Average Trading Volume: 129,146
Technical Sentiment Signal: Buy
Current Market Cap: $321.7M
For a thorough assessment of CLLS stock, go to TipRanks’ Stock Analysis page.